Discovering Tomorrow’s Medicines Today

Dr. Sophie Venet (pictured) closely examines the telltale tracks of a culture sample in a petri dish. Welcome to Novimmune! A Swiss biotech company focused
on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.

Breakthrough Targeted Medicines

Explore our pipeline of novel antibodies to treat inflammatory and immune-related diseases, cancer, and orphan indications.


World-Class Talent and Experience

Meet some of the people
who have made our scientific research and clinical develop-ment advances possible.


Cutting-Edge Technology Platforms

Peek inside our proprietary technology plaforms which are used to generate monoclonal and bispecific antibodies.


Helping Patients
Heal Themselves

Discover how the human immune system works and how antibody drug therapy can help restore patient health.

NEWS: Novimmune announces departure of chief financial officer
Novimmune announced that its chief financial officer, Andrew J. Oakley, is leaving the company to take up a CFO role with a publicly listed company in the UK. A search for a replacement is underway.
(17 NOV 2014)

NEWS: Novimmune executive hits the road in '700 Miles to Hope' charity bicycle ride
Chief business officer, Adrian Mills, joined fourteen other participants in a five-state, seven day bicycle ride to increase awareness of serious childhood disease HLH. The event raised $350,000 for the HLH Center of Excellence at Cincinnati Children's Hospital.
(11 OCT 2014)

NEWS: Novimmune sponsors Akin Foundation '700 Miles to Hope' bicycle ride, October 4 through 10
Novimmune announced that it will be a Supporting Sponsor of the Matthew and Andrew Akin Foundation "700 Miles to Hope" bicycle ride to benefit the HLH Center of Excellence at Cincinnati Children's Hospital Medical Center in Ohio.
(24 SEP 2014)

NEWS: Novimmune appoints Adrian Mills as Chief Business Officer and member of the Executive Committee
Novimmune announced that veteran GlaxoSmithKline executive Adrian Mills has joined the company as Chief Business Officer and member of the Executive Committee.
(10 SEP 2014)

NEWS: Novimmune announces the successful completion of Phase I clinical trial for NI-0101
Novimmune announced the successful completion of a comprehensive Phase I clinical trial investigating the pharmacokinetics, pharmaco-dynamics, preliminary tolerability and safety of NI-0101, a first-in-class monoclonal antibody against toll-like receptor 4 (TLR4).
(05 AUG 2014)